[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rhinitis-viral\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rhinitis-viral":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100622428","rhinavevaluation-of-treatments-for-acute-viral-rhinitis-rhinosinusitis-and-rhinopharyngitis-100622428",false,"NCT07383493","RhinAV_Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and Rhinopharyngitis","Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and Rhinopharyngitis","RhinAV","Inclusion Criteria:\n\n* Acute viral rhinitis or acute rhinosinusitis or viral rhinopharyngitis (sneezing, rhinorrhea, nasal obstruction, cough secondary to posterior rhinorrhea, sore throat) that began less than 72 hours prior to the inclusion visit, in the investigator's judgment,\n* Effective contraception for female patients of childbearing age.\n* Cooperation and sufficient understanding to comply with the requirements of the trial.\n* Acceptance of registration in the SI-RIPH VRB file.\n* Having received informed information and agreeing to give written consent.\n* Affiliated with the French Social Security system.\n\nExclusion Criteria:\n\n* Hypersensitivity\u002Fhistory of allergy to any of the product's components,\n* Complicated rhinitis, rhinosinusitis, or rhinopharyngitis (acute bacterial sinusitis, acute otitis media, acute bronchitis, or pneumonia) or severe cough that is poorly tolerated,\n* Chronic rhinosinusitis,\n* Allergic rhinosinusitis,\n* Other ongoing treatments for acute rhinitis (local treatment, antitussives, antibiotics, antiretrovirals, corticosteroids, etc.),\n* Positive antigen test for influenza A\u002FB or COVID-19 and infection requiring etiological treatment according to the recommendations,\n* Bacterial rhinopharyngitis with positive TROD test\n* Comorbidities or health conditions deemed incompatible with the trial by the investigator,\n* Recent ENT surgery (\\\u003C6 months),\n* ENT pathology such as nasal septum deviation or other causes of nasal obstruction,\n* Pulmonary pathology (COPD, asthma, etc.),\n* Immunosuppression (as reported by the patient),\n* Pregnant or breastfeeding women,\n* Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial,\n* Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).","ALL","18 Years","70 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this study is to conduct post-marketing clinical follow-up of four products: NS, NHE, NHG, and PIR. This follow-up will consist of collecting clinical data in real-life conditions to confirm the tolerance, safety, and efficacy of medical devices used in the treatment of acute viral rhinitis, rhinosinusitis, and rhinopharyngitis, while also assessing the benefit\u002Frisk ratio of the products.",[28,29,30,31,32,33],"Rhinitis Acute","Rhinitis Viral","Rhinosinusitis Acute","Rhinopharyngitis","Rhinitis","Rhinosinusitis","RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-15","ACTUAL",{"date":40,"type":38},"2026-02-25",{"date":42,"type":22},"2027-03",{"name":44,"class":45},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100613522","evaluation-of-a-hypertonic-seawater-aerosol-therapy-solution-in-adults-and-children-100613522","NCT07267689","Evaluation of a Hypertonic Seawater Aerosol Therapy Solution in Adults and Children","Performance and Safety Evaluation of a Hypertonic Seawater Aerosol Therapy Solution in Adults and Children With Upper Respiratory Tract Infection: a Prospective and Multicenter Study","AIR","Inclusion Criteria:\n\n1. Adult subject voluntarily given informed consent to investigation participation in writing encompassing consent to data recording and verification procedures.\n2. Minor subjects (7-17 years old) given informed assent to investigation participation in writing encompassing consent to data recording and verification procedures\n3. Male and female subjects, aged from 2 years old;\n4. Subject diagnosed with URTIs such as rhinopharyngitis, rhinitis, acute rhinosinusitis or cold based on the medical examination done by the doctor.\n5. Subject willing to adhere to the requirements of the protocol, including availability for follow-up visits\n6. Subject who agrees to no use decongestants, corticosteroids, antibiotics, allergen-specific immunotherapy, antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), local nasal antiseptics, other nasal saline solutions or irrigations, nasal sprays, nasal creams or gels, systemic analgesics or antipyretics (except paracetamol if needed);\n7. Subject who is able to comply with the study requirements, at the Investigator's appreciation.\n8. For minor (\\\u003C18) subjects, parents\u002Fguardians willing and able to sign written consent\n9. Subject able and willing to use an internet-enabled device (computer, tablet, or smartphone) to complete study procedures (online questionnaires) and have regular access to a device with internet connectivity (personal or household device) for the duration of the study.\n\nExclusion Criteria:\n\n1. Person with hypersensitivity to seawater\n2. Subject who previously undergone bronchospasm\n3. Children under 2 years of age\n4. Pregnant and breastfeeding women\n5. Onset of URTI symptoms \\> 48 hours\n6. Subject with COVID or flu\n7. Subject presenting alarm symptoms (periorbital oedema\u002Ferythema, displaced globe, double vision, ophthalmoplegia, reduced visual acuity, severe headache, frontal swelling, signs of sepsis, sign of meningitis, neurological signs) at the day of inclusion\n8. Subject known to have allergy to the components of the masks that is used with the inhalation device;\n9. Subject with asthma,\n10. Subject presenting infection or pathology of the inferior respiratory tracts;\n11. Subject with chronic nasal obstruction (polypes)\n12. Subject who used any decongestants, corticosteroids, antibiotics or allergen-specific immunotherapy within 4 weeks prior to inclusion;\n13. Subject who used any antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs) or local nasal antiseptics within 7 days prior to inclusion;\n14. Subject who used any nasal saline solutions or irrigations, nasal sprays, nasal creams or gels, systemic analgesics or antipyretics within 24 hours prior to inclusion;\n15. Subject with drug or alcohol abuse\n16. Subjects who is deprived for their freedom by administrative or legal decision\n17. Subject living in a social or sanitary establishment.\n18. Subject being in an exclusion period for a previous study or with a current or recent (\\\u003C3 months) participation in another investigational study involving a drug or combined device with drug.\n19. Other condition preventing the subject to participate the study in the investigator's opinion: subject deemed unreliable or incapable of understanding and complying with the study assessment or unrealistic expectations of treatment results","2 Years",{"count":57,"type":22},110,[25],"The purpose of this study is to evaluate the tolerance, the performance and safety of this device, 22‰ Hypertonic seawater aerosol therapy solution in unidose container, to treat adult and peadiatric patients with of upper respiratory tract infection such as rhinopharyngitis, rhinitis, acute rhinosinusitis or cold.\n\nThe main questions it aims to answer are to assess if the 22‰ Hypertonic seawater solution used as aerosol therapy solution for inhalation:\n\n* improve nasal symptoms relief;\n* improve sleep quality;\n* improve mucus fluidizing;\n* is safe and well tolerated.\n\nThe study is none comparative and will assess prospectively the symptomatic and functional benefits, the tolerance and the general safety of the medical device when used as an aerosol therapy solution, measured by change from baseline.\n\nTreatments will be done at home and participants will be required to perform two on sites visits and to complete questionnaires and scales for 7 consecutive days from the treatment starting.",[61,28,31,62,29],"Upper Resp Tract Infection","Cold Symptom",[64,65,66,67],"hypertonic seawater","upper respiratory tract infection (URTIs)","inhalation","nebulization","2026-05-18",{"date":70,"type":38},"2026-05-19",{"date":72,"type":38},"2026-04-21",{"date":74,"type":22},"2026-06",{"name":76,"class":77},"Laboratoires Gilbert","INDUSTRY",6]